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Abstract
The racial diversity and gender distribution of HIV-infected patients make it essential to confirm the safety and
efficacy of raltegravir in these populations. A multicenter, open-label, single-arm observational study was
conducted in a diverse cohort of HIV-infected patients (goals: ‡ 25% women; ‡ 50% blacks in the United States),
enrolling treatment-experienced patients failing or intolerant to current antiretroviral therapy (ART) and
treatment-naive patients (limited to £ 20%). All patients received raltegravir 400 mg b.i.d. in a combination
antiretroviral regimen for up to 48 weeks. A total of 206 patients received study treatment at 34 sites in the
United States, Brazil, Dominican Republic, Jamaica, and South Africa: 97 (47%) were female and 153 (74%) were
black [116 (56%) in the United States]. Of these, 185 patients were treatment experienced: 97 (47%) were failing
and 88 (43%) were intolerant to current therapy; 21 patients (10%) were treatment naive. Among treatment-
intolerant patients, 55 (63%) had HIV-1 RNA < 50 copies/ml at baseline. Overall, 15% of patients discontinued:
13% of men, 18% of women, 14% of blacks, and 17% of nonblacks. At week 48, HIV RNA was < 50 copies/ml in
60/94 (64%) patients failing prior therapy, 61/80 (76%) patients intolerant to prior therapy, and 16/21 (76%)
treatment-naive patients. Response rates were similar for men vs. women and black vs. nonblack patients. Drug-
related clinical adverse events were reported by 8% of men, 18% of women, 14% of blacks, and 9% of nonblacks.
After 48 weeks of treatment in a diverse cohort of HIV-infected patients, raltegravir was generally safe and well
tolerated with potent efficacy regardless of gender or race.
Introduction
At the end of 2009, women represented more than half ofthe 33.3 million people with HIV infection worldwide.1
The majority (68%) of people with HIV infection live in sub-
Saharan Africa, where 60% of all cases are in women, and
levels of new HIV infections are higher among women.1 In the
United States in 2010, women accounted for 21% of all diag-
noses of HIV infection, sand blacks/African-Americans con-
tinued to experience the most severe HIV burden, accounting
for 46% of infections,2 even though they represent only 14% of
the U.S. population. The rate of new HIV infections is 15 times
higher in black women than in white women and 6.5 times
higher in black men than in white men.3 Both gender and race
influence HIV-1 RNA levels and the rate of decline in CD4 cell
counts over time,4 the principal measures used to provide
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prognostic information and guide treatment decisions.
Guidelines for the treatment of HIV infection are based largely
on data from clinical trials,5 yet women and racial minori-
ties have been underrepresented in clinical trials of HIV
therapy.6–9
Raltegravir (ISENTRESS) is an HIV integrase inhibitor that
has been shown to be generally safe and well tolerated, with
potent antiretroviral activity in treatment-experienced pa-
tients10–14 and treatment-naive patients16–20 with HIV-1 in-
fection. Phase III studies have demonstrated the durable
antiretroviral effect and favorable long-term safety profile of
raltegravir in both treatment-experienced21 and treatment-
naive patients22; however, only 15% of the patients in these
studies were women and only 12% were black. Given that
HIV-infected patients include increasing numbers of women
and persons from diverse racial and ethnic backgrounds,
additional data are needed on the efficacy and safety of ral-
tegravir in these patient populations.
The REALMRK study was conducted to evaluate the
safety, tolerability, and antiretroviral activity of raltegravir in
a diverse cohort of HIV-infected patients who were primarily
treatment experienced and included substantial numbers of
women and black patients. This report summarizes data on all
study participants through the end of the 48-week treatment
period and the 14-day posttreatment follow-up period. In
addition, this study utilized population pharmacokinetic (PK)
methods to explore the impact of PK variability on the safety
and efficacy of raltegravir in this diverse patient population.
Materials and Methods
Study design
REALMRK (Protocol 055; NCT #00764946) was a multi-
center, open-label, single-arm study conducted at 34 sites (28
in the United States, two in Brazil, two in South Africa, one in
Jamaica, and one in the Dominican Republic) in approxima-
tely 200 HIV-infected patients ‡ 16 years old. The protocol
was approved by the Institutional Review Board or Ethical
Review Committee at each site and conducted in accor-
dance with Good Clinical Practice guidelines. All participants
provided written informed consent. The study enrolled
treatment-experienced patients who were failing or intolerant
to other licensed antiretroviral therapy (ART), as well as
treatment-naive patients; however, because raltegravir was
not approved for use in treatment-naive patients when the
study began, enrollment was monitored to ensure that no
more than 20% of enrolled patients were treatment naive. In
addition, the protocol specified that the study population was
to include at least 25% women and 50% African-Americans
(black patients enrolled in the United States).
Specific recruitment strategies were used to ensure that the
enrollment goals were achieved. Potential study sites were
queried regarding their ability to enroll women (at least two)
and black patients (at least four), and enrollment of men and
nonblack patients was limited by the IVRS managed enroll-
ment system. A 2-year enrollment period was planned in or-
der to have sufficient time to find the appropriate patients.
Recent studies have found higher discontinuation rates in
women than in men23,24; therefore, we also used specific re-
tention strategies such as selecting patients who could meet
the study’s time commitment and supporting their continued
participation through educational programs and events,
follow-up phone calls between study visits, and reimburse-
ment for travel and childcare expenses.
All patients were assigned to raltegravir 400 mg b.i.d. in
combination with other antiretroviral agents for 48 weeks. At
baseline, the site investigator selected the other antiretroviral
agents for each patient on the basis of current treatment
guidelines, the patient’s prior treatment history (including
reasons for discontinuing prior antiretroviral agents), the
results of HIV-1 genotypic and phenotypic antiretroviral re-
sistance testing at screening, and prior genotypic and phe-
notypic antiretroviral resistance testing (including history of
mutations), if available. After a screening visit, patients
who met enrollment criteria returned to the study center for
scheduled procedures on day 1 (initiation of therapy); weeks
4, 8, 16, 24, 36, and 48; and 14 days after completion of study
treatment for a follow-up visit. If a patient discontinued prior
to study completion, all final visit procedures were to be
performed at the time of discontinuation. Medication adher-
ence was monitored with diary cards and tablet counts. At the
day 1 visit, each patient was given a diary card to record
study drug administration, including their background anti-
retroviral therapy. Completed diary cards were to be returned
at each scheduled visit and reviewed with the study coordi-
nator for completeness and accuracy. All containers of study
drug were to be returned at each visit so that the number of
tablets remaining could be determined and recorded.
HIV-1 RNA levels were measured at a central laboratory
using the standard COBAS Amplicor HIV-1 Monitor assay
(version 1.5; Roche Diagnostics, Branchburg, NJ) with a lower
limit of quantification of 400 copies/ml and the Ultrasensitive
Amplicor HIV-1 Monitor assay (version 1.5; Roche Diag-
nostics) with a lower quantification limit of 50 copies/ml.
Blood samples were collected from all patients to determine
resistance to antiretroviral agents at screening, weeks 24 and
48, and if applicable, at early discontinuation and to confirm
virologic failure. In patients demonstrating viral rebound
(HIV RNA ‡ 50 copies/ml after initial response with HIV
RNA < 50 copies/ml; or > 1.0 log10 increase in HIV RNA
above nadir level) or nonresponse (confirmed decrease of
< 1.0 log10 from baseline in HIV RNA and HIV RNA ‡ 50
copies/ml starting at week 24 or beyond; or decrease of < 1.0
log10 from baseline in HIV RNA and HIV RNA ‡ 50 copies/ml
at early discontinuation), resistance to raltegravir and other
ART in the treatment regimen was assessed if the viral load
exceeded 400 copies/ml, the nominal limit of detection for the
genotypic and phenotypic resistance assays utilized in this
study (performed by Monogram Biosciences, South San
Francisco, CA).
Plasma samples for measurement of raltegravir concen-
trations were collected in all patients at day 1 (predrug) and
weeks 4, 8, 16, 24, 36, and 48. At weeks 24 and 48, samples
were collected before the morning dose; other samples were
collected irrespective of dosing time. Times of sample collec-
tion and the prior dose were recorded. Plasma samples were
analyzed for raltegravir concentrations at PharmaNet Cana-
da, Inc. (Quebec, Canada). The analytical method for the
determination of raltegravir in human plasma involves iso-
lation, via 96-well liquid–liquid extraction, of the analyte and
internal standard from plasma, followed by HPLC-MS/MS
analysis.25 The lower limit of quantitation for the plasma as-
say was 2 ng/ml (4.5 nM) and the linear calibration range was
2 to 1,000 ng/ml.
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Statistical methods
The primary treatment period for the efficacy analyses was
October 14, 2008 to February 25, 2011. The primary efficacy
endpoint was the proportion of patients with plasma HIV
RNA < 50 copies/ml at week 48. Secondary efficacy end-
points included the proportion of patients with plasma HIV
RNA < 400 copies/ml and the change from baseline in CD4
cell counts at week 48. Efficacy analyses included all patients
who took at least one dose of study medication and had at
least one postbaseline evaluation. The Treatment-Related
Discontinuation = Failure (TRD = F) approach was the pri-
mary method for handling missing HIV RNA values. For the
change from baseline in CD4 cell count, baseline values were
carried forward for patients who discontinued prior to week
48 due to lack of efficacy [Observed Failure (OF) approach].
The study objectives were addressed via estimation using
descriptive statistics for the total study population as well as
by gender (male, female) and race (black, nonblack) with
patients grouped by treatment experience as follows: treat-
ment experienced, failing current therapy; treatment experi-
enced, intolerant to current therapy; treatment naive. No
hypothesis testing was performed.
All patients who took at least one dose of study medication
were included in the safety analyses. Adverse events occur-
ring during the study or within 14 days after discontinuation
were included. Adverse-event terms were adapted from the
Medical Dictionary for Regulatory Activities (MedDRA ver-
sion 13.0). Adverse events were considered drug related if
judged by the investigator as definitely, probably, or possibly
related to any of the study drugs. The intensity of clinical
adverse events was graded by the investigator as mild,
moderate, or severe. Severity of laboratory abnormalities was
graded according to the 1992 DAIDS toxicity guidelines for
adults.
For the sparse PK sampling data, three summary measures
of the observed concentration data for each patient were cal-
culated to characterize raltegravir pharmacokinetics: GM-
C12h (the geometric mean of all samples for an individual
patient collected between 11 and 13 h after dosing), GM-All
(the geometric mean of all samples for an individual patient,
regardless of time of sample collection), and Cmin (the mini-
mum concentration value of all samples for an individual
patient, regardless of collection time).
Results
Demographics
Of the 206 patients who received study treatment, 97 (47%)
were women, 153 (74%) were black [116 (56%) in the United
States; 37 (18%) ex-United States], and 44 (21%) were Hispanic
or Latino (Table 1). The median age of 45 years (range 20–79)
was similar across subgroups defined by gender and race. A
disproportionate number (39/53; 74%) of nonblack patients
were male. At the time of enrollment, most patients (90%)
were ART experienced; 47% were failing current therapy and
43% were intolerant of current therapy. The small subgroup of
treatment-naive patients (N = 21, 10%) had a median age 8–10
years younger than treatment-experienced failing and intol-
erant patients, respectively, and a disproportionate number
(67%) were male. ART-experienced patients who were intol-
erant of their most recent therapy had lower HIV RNA levels
and higher CD4 counts at baseline than patients who were
failing their most recent therapy and those who were treat-
ment naive (Table 1). Antiretroviral agents selected by the
investigator as background therapy during the study in-
cluded emtricitabine/tenofovir (53%), ritonavir (41%), dar-
unavir (26%), and lopinavir/ritonavir (21%).
Disposition
Overall, 175 patients (85%) completed the study: 87% of
men and 82% of women; 86% of black patients and 83% of
nonblack patients (Fig. 1A). Discontinuation due to an ad-
verse event was less common in men (1/109, 1%) than in
women (5/97, 5%) but was similar for black patients (5/153,
3%) and nonblack patients (1/53, 2%). Other reasons for dis-
continuation are shown in Fig. 1A. The study was completed
by 87% of patients who failed their most recent therapy, 81%
of patients intolerant of their most recent therapy, and 82% of
previously untreated patients (Fig. 1B). Discontinuation rates
due to adverse events were similar across the treatment-ex-
perienced categories (3%, 2%, and 5%, respectively). Medi-
cation adherence ‡ 90% was reported by 95% (195/206) of
all treated patients, including 94% (103/109) of males, 95%
(92/97) of females, 95% (145/153) of black patients, and 94%
(50/53) of nonblack patients.
Efficacy
After 48 weeks of treatment with raltegravir, an HIV-1
RNA level < 50 copies/ml was achieved in 64% of treatment-
experienced patients failing their most recent therapy prior
to the current study (Table 2) and in 76% of treatment-
experienced patients intolerant of their prior therapy (of
whom, 63% had HIV-1 RNA < 50 copies/ml at baseline).
Among the small number of treatment-naive patients followed
in this study, 76% had an HIV-1 RNA level < 50 copies/ml at
the end of the study. In all three treatment categories, response
rates were similar between men and women (Fig. 2A–C).
Response rates were also similar between black and non-
black patients who were failing prior therapy (Fig. 2A) and
those who were treatment naive (Fig. 2C). Among treatment-
experienced patients intolerant of prior therapy, an HIV-1 RNA
level < 50 copies/ml was achieved in 69% of black patients and
100% of nonblack patients (Fig. 2B). Overall virologic response
rates were 69% for black men [46/67, 95% CI (56, 79)] and 71%
for black women [52/73, 95% CI (59, 81)], compared with 81%
for nonblack men [30/37, 95% CI (65, 92)] and 75% for
nonblack women [9/12, 95% CI (43, 95)]. The mean change in
CD4 cell count from baseline to week 48 was 134 cells/ll in
patients failing prior therapy, 64 cells/ll in patients intol-
erant to prior therapy, and 193 cells/ll in treatment-naive
patients (Table 2). Within each treatment-experienced cate-
gory, the mean change in CD4 count was similar between
men and women and between black and nonblack patients
(Table 2).
Resistance
Virologic failure was confirmed in 48 (23%) of 206 treated
patients by week 48. Genotypic and phenotypic resistance
testing was performed for 38 patients. Eleven patients had
viral isolates that displayed primary raltegravir resistance
mutations, including one in Y143, six in Q148, and six in N155
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(two patients had variants of both Q148 and N155). These 11
patients were treatment experienced, and nine had failed their
most recent ART. Among the 27 patients with virologic failure
whose viruses did not display a primary raltegravir resistance
mutation (143, 148, or 155), two patients had viruses with
other known raltegravir resistance mutations. A viral isolate
from a previously treatment-naive patient exhibited the
I203I/M mutation but retained phenotypic sensitivity to ral-
tegravir. Of note, virus isolated from one nonresponder had
the L74I integrase polymorphism present in both baseline and
virologic failure isolates; L74I is not known to confer reduced
susceptibility to raltegravir, consistent with the observation
that the patient’s baseline virus was sensitive to raltegravir.
However, virus isolated from this patient after virologic fail-
ure also had a treatment-emergent integrase mutation, F121C,
which has been shown to confer raltegravir resistance in
phenotypic assays (data on file at Merck).
Pharmacokinetics
Raltegravir PK parameters calculated from sparse sam-
pling were consistent with expectations based on prior studies




intolerant to prior therapy Treatment naive Total
(N = 97) (N = 88) (N = 21) (N = 206)
Gender, n (%)
Male 51 (52.6) 44 (50.0) 14 (66.7) 109 (52.9)
Female 46 (47.4) 44 (50.0) 7 (33.3) 97 (47.1)
Race, n (%)
White 19 (19.6) 17 (19.3) 6 (28.6) 42 (20.4)
Black 70 (72.2) 69 (78.4) 14 (66.7) 153 (74.3)
Native American 1 (1.0) 1 (1.1) 0 (0.0) 2 (1.0)
Multiracial 7 (7.2) 1 (1.1) 1 (4.8) 9 (4.4)
Ethnicity, n (%)
Hispanic or Latino 27 (27.8) 12 (13.6) 5 (23.8) 44 (21.4)
Region, n (%)
North America 76 (78.4) 85 (96.6) 20 (95.2) 181 (87.9)
Southern Africa 10 (10.3) 2 (2.3) 1 (4.8) 13 (6.3)
South America 11 (11.3) 1 (1.1) 0 (0.0) 12 (5.8)
Age (years)
Mean (SD) 44.0 (9.2) 46.9 (9.0) 38.5 (10.1) 44.7 (9.5)
Median (min, max) 45.0 (20.0, 73.0) 47.0 (22.0, 79.0) 37.0 (23.0, 60.0) 45.0 (20.0, 79.0)
CD4 cell count (cells/ll)
Mean (SD) 217.7 (180.9) 417.5 (272.5) 184.6 (112.0) 299.7 (242.0)
Median (min, max) 190.0 (5.0, 1073.0) 374.5 (4.0, 1274.0) 168.0 (2.0, 387.0) 236.0 (2.0, 1274.0)
Plasma HIV RNA1 (log10 copies/ml)
Mean (SD) 4.1 (1.1) 2.5 (1.4) 4.8 (1.1) 3.5 (1.5)
Median (min, max) 4.2 (1.4, 5.9) 1.7 (1.4, 5.5) 4.9 (1.7, 5.9) 3.8 (1.4, 5.9)
Plasma HIV RNA1 (copies/ml)
Mean (SD) 94,903.2 (182,204) 26,147.7 (65,843.3) 229,668 (263,742) 79,270.0 (166,784)
Median (min, max) 15,100 (25, 750,001) 49 (25, 327,000) 85,700 (49, 750,001) 6,440 (25, 750,001)
Hepatitis infection, n (%)
Hepatitis B or C positive2 13 (13.4) 12 (13.6) 2 (9.5) 27 (13.1)
Viral subtype, n (%)
Clade B 75 (77.3) 22 (25.0) 18 (85.7) 115 (55.8)
Non-clade B 13 (13.4) 2 (2.3) 2 (9.5) 17 (8.3)
Missing 9 (9.3) 64 (72.7) 1 (4.8) 74 (35.9)
Baseline plasma HIV RNA,3 n (%)
£ 50 copies/ml 2 (2.1) 55 (62.5) 1 (4.8) 58 (28.2)
> 50 copies/ml 95 (97.9) 33 (37.5) 20 (95.2) 148 (71.8)
> 100,000 copies/ml 20 (20.6) 9 (10.2) 9 (42.9) 38 (18.4)
£ 100,000 copies/ml 77 (79.4) 79 (89.8) 12 (57.1) 168 (81.6)
Baseline CD4 cell counts, n (%)
£ 50 cells/mm3 16 (16.5) 5 (5.7) 3 (14.3) 24 (11.7)
> 50 and £ 200 cells/mm3 36 (37.1) 16 (18.2) 9 (42.9) 61 (29.6)
> 200 cells/mm3 45 (46.4) 67 (76.1) 9 (42.9) 121 (58.7)
1RNA Amplicor Ultrasensitive assay values reported as ‘‘ < 50 copies/ml HIV RNA detected’’ were imputed by 50 copies/ml, and values
reported as ‘‘ < 50 copies/ml HIV RNA not detected’’ were imputed as 25 copies/ml.
2Evidence of hepatitis B surface antigen, hepatitis C antibody, and HCV RNA (by HCV Taqman quantitative test).
3Patients with missing results were excluded.
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of raltegravir 400 mg b.i.d., regardless of patients’ gender or
race (Table 3). Logistic regression models were used to ex-
plore the potential association between raltegravir PK pa-
rameter values and antiretroviral responses (Table 4). One
statistically significant ( p < 0.05) association was observed
between virologic failure and GM-All. The average GM-All
was slightly lower in patients with virologic failure, but there
was significant overlap in GM-All values between this group
and patients without virologic failure. No threshold value of
GM-All below which most patients fail was evident from the
data. There were also trends toward associations between all
of the efficacy endpoints and GM-C12h, although none of
these relationships was statistically significant.
Safety
Clinical adverse events were reported in 72% of all patients
who received raltegravir: 75% of men vs. 69% of women and
70% of black vs. 79% of nonblack patients. Clinical adverse
events were considered related to raltegravir (alone or in
combination with background ART) in 13% of patients
overall; the most common drug-related clinical adverse
events were nausea (4%), diarrhea (2%), and vomiting (2%).
Drug-related clinical adverse events were reported in 8% of
men and 18% of women. The difference was largely attrib-
utable to the broad category of gastrointestinal (GI) disorders,
which were considered drug related in 6% of men vs. 10% of
women, although rates of the most common drug-related GI
events were the same in men and women (nausea 4%, vo-
miting 2%, and diarrhea 2%). Clinical adverse events related
to raltegravir were reported in 14% of black patients and 9% of
nonblack patients. Rates of drug-related adverse events were
similar in black men (7%) and nonblack men (10%) but were
higher in black women (19%) than in nonblack women (7%).
None of the most common drug-related adverse events was
reported by nonblack women (Table 5).
FIG. 1. Patient disposition
by gender and race (A) and by
prior treatment experience (B).
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A total of 28 serious clinical adverse events were reported
in 21 patients (10%); in four patients (2%), these events were
considered drug related. Serious clinical adverse events oc-
curred in 11% of men, 9% of women, 10% of black patients,
and 9% of nonblack patients. The most common serious ad-
verse events were various infections, as would be expected in
patients immunocompromised due to HIV. Cryptococcal men-
ingitis was diagnosed in two patients and pneumonia (including
a case due to Pneumocystis jirovecii) was diagnosed in three pa-
tients. All other serious clinical events were single instances.
Two patients died on the study as a result of serious clinical
events: one patient with deep vein thrombosis and one with
malignant bone neoplasm; these events were considered unre-
lated to the study medication. One patient had a serious event of
rhabdomyolysis, which was considered related to raltegravir:
CPK was mildly elevated at randomization (160 IU/liter) and on
day 60 (199 IU/liter). On day 72, the patient went to the emer-
gency room with calf pain and dark urine; CPK was 8,141 IU/
liter (grade 4), and raltegravir was stopped. About 2 months
later (day 127) CPK had fallen to 231 IU/liter (grade 0). The
patient’s urine toxicology screen on day 72 was positive for
cocaine, which can cause rhabdomyolysis.
Laboratory adverse events occurred in 11% of all treated
patients (10% of men, 12% of women, 10% of blacks, and 13%
of nonblacks) and were considered drug related in 2%. One
patient had a serious laboratory adverse event (Grade 4 ele-
vation of ALT), which led to discontinuation and was con-
sidered unrelated to the study drug. No deaths occurred as a
result of a laboratory adverse event. Increased ALT and AST
(grade 2 or higher) were slightly more common in men (5%
and 6%, respectively) than women (3% and 2%, respectively)
and were less common in black patients (both 3%) than in
nonblack patients (both 8%). Increased creatine kinase (grade
2 or higher) was more common in men (10%) than women
(0%) but occurred with similar frequency in blacks (5%) and
nonblacks (6%). Rates of increased serum cholesterol (grade 2
or higher) were similar between men (12%) and women (10%)
and between blacks and nonblacks (both 11%). The propor-
tion of patients with laboratory abnormalities of Grade 2 or
higher is displayed by gender and race in Table 5.
Discussion
Raltegravir 400 mg b.i.d. is approved for the treatment of
HIV-1 infection in combination with other ART. The HIV-
infected population includes increasing numbers of women
and patients from diverse racial and ethnic backgrounds, but
these groups are often underrepresented in clinical trials of new
HIV therapy. In the phase III development program for ralte-
gravir, 15% of study patients were female and 12% were black;
therefore, the goal of this study was to increase our knowledge
about the efficacy and safety of raltegravir in these patients
by enrolling at least 25% women and at least 50% African-
Americans. The 206 patients who participated in REALMRK
included 97 women (47%) and 153 black patients (74%), of
whom 116 were African-American. The study population was
further diversified by enrolling patients with different cate-
gories of treatment experience, including 47% who were failing






to prior therapy Treatment naive
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
Proportion of Patients with Plasma HIV RNA < 50 copies/mla
Total 60/94 63.8 (53.3, 73.5) 61/80 76.3 (65.4, 85.1) 16/21 76.2 (52.8, 91.8)
Male 33/50 66.0 (51.2, 78.8) 33/41 80.5 (65.1, 91.2) 10/14 71.4 (41.9, 91.6)
Female 27/44 61.4 (45.5, 75.6) 28/39 71.8 (55.1, 85.0) 6/7 85.7 (42.1, 99.6)
Black (U.S. + ex-U.S.) 44/69 63.8 (51.3, 75.0) 43/62 69.4 (56.3, 80.4) 11/14 78.6 (49.2, 95.3)
Nonblack 16/25 64.0 (42.5, 82.0) 18/18 100.0 (81.5,100.0) 5/7 71.4 (29.0, 96.3)
Baseline HIV RNA £ 50 copies/mL* 44/50 88.0 (75.7, 95.5)






to prior therapy Treatment naive
N Mean change (95% CI) N Mean change (95% CI) N Mean change (95% CI)
Change from Baseline in CD4 Cell Countb (cells/ml)
Total 89 134 (107, 160) 76 64 (34, 93) 19 193 (117, 268)
Male 48 111 (77, 145) 38 55 (15, 94) 13 146 (59, 232)
Female 41 161 (120, 202) 38 73 (27, 119) 6 294 (140, 448)
Black (U.S. + ex-U.S.) 66 141 (110, 173) 61 62 (27, 98) 12 209 (109, 309)
Nonblack 23 113 (62, 164) 15 69 (17, 122) 7 164 (13, 316)
aMissing values handled with Treatment-Related Discontinuation = Failure (TRD = F) approach.
*Among treatment experienced patients intolerant to prior therapy.
bMissing values handled with Observed Failure (OF) approach.
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their most recent ART, 43% who were intolerant of their most
recent ART, and 10% who were treatment naive. Baseline HIV-
1 RNA levels and CD4 counts varied with prior treatment ex-
perience. Despite the diversity of the population, the 48-week
completion rate was high overall (85%) and within subgroups
defined by gender and race. This retention rate is comparable
to, if not better than, other contemporary HIV trials in diverse
patient populations.23,24
At completion of the study treatment, 64% of patients who
were prior treatment failures had HIV-1 RNA levels < 50
FIG. 2. Percent of patients with HIV-1 RNA < 50 copies/
ml [Treatment-Related Discontinuation = Failure (TRD = F)]
by gender (top panels) and by race (bottom panels) in
treatment-experienced patients failing prior therapy (A), in
treatment-experienced patients intolerant of prior therapy
(B), and in treatment-naive patients (C).
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copies/ml, as did 76% of previously intolerant patients (in-
cluding both those who were suppressed and those who were
not suppressed at the time of study initiation) and 76% of
treatment-naive patients. At week 48, mean CD4 cell counts
had increased in all patient subgroups, although the CD4 re-
sponse was lower in patients intolerant to prior therapy than in
prior treatment failures and treatment-naive patients; this dif-
ference was most likely related to the higher baseline CD4 cell
count (418 cells/ll) in the previously intolerant group. By week
48, 23% of patients had experienced virologic failure. Across all
Table 3. Summary Statistics for Raltegravir Sparse Pharmacokinetic Parameters by Gender and Race
PK parameter N LS mean (95% CI)a %CVb Median Min Max
Female
GM all (nM) 91 338 (273, 419) 147 330 14 7,039
GM C12 (nM) 60 331 (251, 437) 137 311 57 6,394
Cmin (nM) 91 99 (76, 128) 196 96 6 4,566
Male
GM all (nM) 105 381 (312, 466) 134 344 5 5,800
GM C12 (nM) 58 282 (212, 374) 165 274 7 15,291
Cmin (nM) 105 83 (65, 105) 197 80 5 5,800
Black
GM all (nM) 146 353 (298, 418) 121 302 29 5,800
GM C12 (nM) 90 285 (227, 357) 139 274 7 6,394
Cmin (nM) 146 93 (76, 115) 189 89 6 5,800
Nonblack
GM all (nM) 50 385 (288, 514) 203 409 5 7,039
GM C12 (nM) 28 385 (257, 578) 186 336 62 15,291
Cmin (nM) 50 80 (56, 114) 221 86 5 1,154
Female vs. male comparison GMR (90% CI)
GM all female/GM all male 0.89 (0.69, 1.13)
GM C12h female/GM C12h male 1.17 (0.84, 1.64)
Cmin female/Cmin male 1.20 (0.89, 1.61)
Black vs. nonblack comparison GMR (90% CI)
GM all black/GM all nonblack 0.92 (0.69, 1.22)
GM C12h black/GM C12h nonblack 0.74 (0.50, 1.09)
Cmin black/Cmin nonblack 1.17 (0.83, 1.64)
aBack-transformed from log scale. LS mean, geometric least-squares mean.
b%CV = 100 · sqrt[exp(s2) - 1], where s2 is the observed variance on the natural log-scale.
Note: Raltegravir was administered with background antiretroviral therapy.
min, minimum; max, maximum; CI, confidence interval; CV, coefficient of variation; PK, pharmacokinetic; GM, geometric mean.
Table 4. Sparse Pharmacokinetic Parameters as a Predictor for Antiretroviral Responses at Week 48
na Na Odds ratio (95% CI)b p-valueb
HIV RNA < 400 at week 48c
GM all (nM) 152 185 1.246 (0.510, 3.040) 0.630
GM C12h (nM) 98 115 2.578 (0.740, 8.978) 0.137
Cmin (nM) 152 185 0.691 (0.321, 1.489) 0.345
HIV RNA < 50 at week 48
GM all (nM) 137 184 1.332 (0.615, 2.882) 0.467
GM C12h (nM) 88 114 2.379 (0.841, 6.725) 0.102
Cmin (nM) 137 184 0.988 (0.517, 1.888) 0.971
Virologic failured
GM all (nM) 42 185 0.428 (0.187, 0.977) 0.044
GM C12h (nM) 22 115 0.393 (0.132, 1.166) 0.092
Cmin (nM) 42 185 0.684 (0.349, 1.340) 0.269
aN, number of patients with both PK and efficacy data. n, number of patients (out of N) with events.
bLogistic regression with the following covariates: baseline HIV RNA (log10 copies/ml) and PK parameters (in log10 scale).
cFor HIV RNA < 400 at week 48, a reliable estimate of odds ratio with corresponding p-value cannot be obtained due to the low number of
subjects who failed this criterion.
dVirologic failure was defined as (1) nonresponders who had a confirmed < 1.0 log10 decrease from baseline plasma HIV RNA and HIV
RNA > 50 copies/ml starting at week 24 or beyond, or (2) viral rebound starting at week 24 or beyond, which was defined as (a) HIV RNA
> 50 copies/ml (on two consecutive measurements at least 1 week apart) after initial response with HIV RNA < 50 copies/ml, or (b) > 1.0
log10 increase in HIV RNA above nadir level (on two consecutive measurements at least 1 week apart).
Note: (1) Patients who prematurely discontinued assigned treatment due to lack of efficacy were considered as failures (OF). (2) Raltegravir
(400 mg b.i.d.) was administered with an optimized background therapy.
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of the populations (by treatment history) studied here, fewer
than 50% of patients failing a raltegravir-based regimen had
viruses displaying raltegravir resistance after virologic failure.
This observation is consistent with reports of low raltegravir
resistance rates in patients outside the clinical trial setting.26
Virologic response rates were generally similar between
men and women regardless of prior treatment experience.
Previous studies of raltegravir have also shown similar re-
sponse rates between men and women. In the BENCHMRK
studies (prior treatment failures), 64% of men (249/387) and
64% of women (36/56) had HIV RNA < 50 copies/ml at
week 48.13 In STARTMRK (treatment-naive patients), viro-
logic response rates were 89% for men (183/206) and 96% for
women (45/47) at week 96.19 In SWITCHMRK (treatment-
experienced patients, all of whom had HIV-1 RNA levels < 50
copies/ml for at least 3 months on their prior regimens), re-
sponse rates were 88% for men (233/265) and 97% for women
(60/62) at week 24.27
Other clinical trials that have examined gender-based dif-
ferences in response to HIV therapy include an open-label
study of darunavir/ritonavir in treatment-experienced
patients (the GRACE study23), two open-label studies of
tipranavir/ritonavir vs. ritonavir-boosted comparator prote-
ase inhibitors in treatment-experienced patients (the RESIST
studies28), and an open-label study of atazanavir/ritonavir vs.
lopinavir/ritonavir in treatment-naive patients (the CASTLE
study24). In the RESIST studies,28 the proportion of patients
with viral load < 50 copies/ml was not significantly different
between men and women at week 48. In the GRACE study (48
weeks)23 and the CASTLE study (96 weeks),24 virologic re-
sponse rates were lower in women than in men, but this dif-
ference was attributed to higher discontinuation rates among
women. In our study, the discontinuation rate was slightly
higher in women (18%) than in men (13%), and the potential
impact of this difference on virologic response rates was ad-
justed by counting only treatment-related discontinuations as
failures in the efficacy analyses. CD4 increases tended to be
higher in women than in men in our study, which is consistent
with findings in RESIST28 and GRACE.23
In our study, virologic response rates were similar be-
tween black and nonblack patients who were either prior
treatment failures (both 64%) or treatment naive (79% vs.
71%). Among patients who were intolerant of their prior
therapy, the response rate was lower in black patients (69%)
than in nonblack patients (100%). Overall response rates were
numerically slightly lower among black patients, more so for
men than women, but similar to those in nonblack patients
due to the wide confidence intervals. Comparisons of this
nature should be made cautiously given the potential imbal-
ance of important prognostic factors within each subgroup.
In previous studies of raltegravir, subgroup analyses have
shown virologic response rates to be similar in black and
Table 5. Adverse Events and Laboratory Abnormalities by Gender and Race, n (%)
Male (n = 109) Female (n = 97)
Black (N = 70) Nonblack (N = 39) Black (N = 83) Nonblack (N = 14)
Clinical adverse events (AEs) 52 (74.3) 30 (76.9) 55 (66.3) 12 (85.7)
Drug-relateda AE 5 (7.1) 4 (10.3) 16 (19.3) 1 (7.1)
Serious AE 9 (12.9) 3 (7.7) 7 (8.4) 2 (14.3)
Serious and drug-relateda AE 1 (1.4) 0 3 (3.6) 0
Discontinued due to AE 1 (1.4) 0 3 (3.6) 1b (7.1)
Most common drug-relateda clinical AEs
Abdominal discomfort 0 0 2 (2.4) 0
Diarrhea 1 (1.4) 1 (2.6) 2 (2.4) 0
Nausea 2 (2.9) 2 (5.1) 4 (4.8) 0
Vomiting 1 (1.4) 1 (2.6) 2 (2.4) 0
Myalgia 0 0 2 (2.4) 0
Headache 1 (1.4) 0 2 (2.4) 0
Laboratory AEs 5 (7.1) 6 (15.4) 11 (13.3) 1 (7.1)
Drug-relateda AE 2 (2.9) 1 (2.6) 1 (1.2) 0
Discontinued due to AE 0 0 1 (1.2) 0
Laboratory abnormalities, grade 2 and higher
Absolute neutrophil count 8/70 (11.4) 0 5/81 (6.2) 1/13 (7.7)
Hemoglobin 0 0 1/81 (1.2) 1/13 (7.7)
Platelet count 0 1/39 (2.6) 0 0
Fasting LDL cholesterol 6/56 (10.7) 1/27 (3.7) 7/65 (10.8) 0
Fasting total cholesterol 8/58 (13.8) 5/29 (17.2) 9/69 (13.0) 1/11 (9.1)
Fasting triglycerides 2/58 (3.4) 2/29 (6.9) 2/69 (2.9) 0
Fasting glucose 6/59 (10.2) 1/29 (3.4) 6/67 (9.0) 1/12 (8.3)
Total bilirubin 6/70 (8.6) 3/39 (7.7) 4/81 (4.9) 2/13 (15.4)
Serum creatinine 1/70 (1.4) 1/39 (2.6) 3/81 (3.7) 1/13 (7.7)
Aspartate aminotransferase 2/70 (2.9) 4/39 (10.3) 2/81 (2.5) 0
Alanine aminotransferase 1/70 (1.4) 4/39 (10.3) 3/81 (3.7) 0
Alkaline phosphatase 0 0 2/81 (2.5) 0
Creatine kinase 8/70 (11.4) 3/39 (7.7) 0 0
aDetermined by investigator to be possibly, probably, or definitely related to raltegravir alone or in combination with background ART.
bThis patient discontinued due to an adverse event in the poststudy period.
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nonblack patients, respectively: in BENCHMRK,13 62% (39/
63) vs. 63% (214/339) at week 48; in STARTMRK,19 89% (25/
28) vs. 90% (203/225) at week 96; and in SWITCHMRK,27 86%
(44/51) vs. 90% (249/276) at week 24.
Several cohort studies have compared response to ART by
race/ethnicity and found no difference in CD4 response29,30
or virologic response29,31 based on race. However, more re-
cent studies have found associations between virologic re-
sponse and race. An increased risk for virologic failure in
black patients was found in two ACTG clinical trials32,33 and
in a military cohort study.34 Another military cohort study
found that African-Americans were significantly less likely to
achieve viral suppression than European-Americans,35 and a
longitudinal study in the southeastern United States found
that minority racial/ethnic groups discontinued ART faster
and were more likely to experience virologic failure.36 Results
from the REALMRK study, together with the subgroup ana-
lyses of the Phase III studies, suggest that raltegravir has
similar efficacy in black and nonblack patients.
Raltegravir PK parameters calculated from sparse sam-
pling were consistent with expectations based on prior studies
of raltegravir 400 mg b.i.d.,37 regardless of patient gender or
race. Raltegravir administered in combination with ART for
48 weeks was generally well tolerated, with relatively few
serious drug-related adverse events (2%) and discontinua-
tions due to adverse events (3%). Drug-related adverse events
were more common in women than in men and in black
women compared with nonblack women. Discontinuation
due to an adverse event was also more common in women
than in men, and four of the five women who discontinued
due to an adverse event were black. A trend for higher dis-
continuation rates in women due to adverse events has been
noted with other antiretroviral agents.23,38,39 Raltegravir-
based regimens were well tolerated by patients who were
intolerant of their prior ART: 81% of these patients completed
the study, and only 2% withdrew because of adverse events.
The REALMRK study was neither powered nor designed to
detect differences based on gender or race; it was designed
specifically to generate further safety and efficacy data in
populations that are traditionally underrepresented in clinical
trials. To address anticipated difficulties in conducting an HIV
treatment trial in the patient populations we sought to include,
we implemented specific recruitment and retention strategies
that enabled us to enroll a high proportion of women (47%) and
black patients (74%) and to achieve retention rates > 80%. In
this diverse cohort of HIV-infected, ART-experienced or naive
patients, 48 weeks of therapy with raltegravir 400 mg b.i.d. in
combination with background ART showed sustained anti-
retroviral activity and was generally safe and well tolerated,
regardless of gender or race, and is thus a useful component of
antiretroviral therapy in a broad patient population.
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